Stocks Onyx Pharmaceuticals Inc

More

  • Cramer makes the call on viewers' favorite stocks.

  • Recently I've blogged and raised the question in an interview about whether Onyx Pharmaceuticals might be having a tough time finding a new leader. Well, nearly six months since longtime Chairman and CEO Hollings Renton announced his plans to retire this year, the biotech company has filled the spot.

  • nexavar_logo.jpg

    Almost exactly one year since Onyx Pharmaceuticals announced positive results of its drug Nexavar for liver cancer and the stock doubled in one day, the biopharmaceutical company is providing an example of the ups and downs of drug development and biotech investing.

  • Okay, the real "Granddaddy of 'em all" was actually this past Tuesday at the Rose Bowl (I promise that's my last reference to the amazing USC Trojans unless they win a split national championship), but the granddaddy of healthcare investment conferences begins on Monday in San Francisco.

  • Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • For a Monday before the Thanksgiving holiday, this is turning into an extremely busy day on the biotech beat. Two of the stories actually broke on Sunday: Celgene buying Pharmion for nearly $3 billion and Genentech announcing a breakthrough in brain cancer. Then, before the opening bell this morning Onyx Pharmaceuticals and Bayer won the expected Food and Drug Administration approval of their drug Nexavar for liver cancer.

  • Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • In 1990, Amgen was the risky-but-profitable biotech of choice. Today, its stand-in is Onyx Pharmaceuticals.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • The financial sector continues to get pounded. General Motors reported a significant third-quarter loss, but there is a glimmer of hope in the pharmaceutical industry. 

  • To a five-star fund manager, it's not how big the stars are, but how brightly they're shining.  In the pharmaceutical field, Kris Jenner of T. Rowe Price finds brightness at both ends of the size spectrum.

  • biogenidec_AP.jpg

    For quite some time now analysts and investors have been speculating that big pharma would go on a biotech buying binge. So, will the announcement by Biogen Idec late Friday that it's putting itself on the market be the spark that ignites an M & A explosion in the sector? Perhaps.

  • synta_pharmaceuticals.jpg

    Melanoma -- a type of skin cancer -- is the most common form of cancer. It can spread very quickly and the prognosis often is not good. The American Cancer Society estimates that nearly 60,000 new cases of melanoma will be diagnosed this year and more than 8,000 patients will die. You can find out more about it on the ACS's website.

  • Traders at SIG Specialists trading post on the floor of the New York Stock Exchange talk among themselves shortly after the opening bell Monday, April 18, 2005, in New York.  Stocks regained some stability Monday following a three-day selloff as strong first-quarter earnings and a pair of merger announcements lent some support to a market battered by worries about economic growth.  (AP Photo/Kathy Willens)

    Stocks closed broadly lower at the end of a light-volume trading session as continued weakness in financial stocks brought down the major indexes. The Dow fell 56 points, closing near the lows of the trading session, while the S&P 500 and Nasdaq Composite ended with respective losses of 0.9% and 0.6%, respectively.

  • Bayer and Onyx Pharmaceuticals said they were stopping a late clinical liver cancer trial with Nexavar in the Asia-Pacific region so patients can get the drug sooner after encouraging results.

  • Omniture, Sears, AG Edwards and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Stocks closed with modest gains as investors shrugged off sharp declines in China and higher energy prices amid continued mergers and acquisitions activity. "Right now we're in a glass-half-full type of mood," said Al Goldman, chief market strategist at A.G. Edwards. "The market just doesn't seem to go down."

  • A roundup of the most actively traded biotech and pharma stocks following the annual American Society of Clinical Oncology conference in Chicago.

  • Onyx Pharamaceuticals shares rose sharply after its partner Bayer said results of a Phase 3 study showed that Nexavar significantly extended overall survival in patients with liver cancer by 44%.

  • The American Society of clinical Oncology is underway in Chicago and the high profile, annual cancer conference is producing its usual combination of scientific and financial excitement.

  • Stocks are weaker ahead of the open despite a round of Monday morning mergers. Asian markets were higher, ignoring another selloff in China overnight, and European markets are lower.